ImmVirX

New Lambton, Australia

ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.

$25.0M raised

Jun 2023

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ImmVirX raised?

ImmVirX has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.

Who are ImmVirX's investors?

ImmVirX's investors include OneVentures, Acorn Capital.

Where is ImmVirX headquartered?

ImmVirX is headquartered in New Lambton, Australia.

What does ImmVirX do?

ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.

What stage is ImmVirX at?

ImmVirX is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 5, 2023.

MLA

"ImmVirX — Funding & Investors." VCBacked, June 5, 2023, https://www.vcbacked.co/company/immvirx. Accessed July 3, 2026.

APA

VCBacked. (2023). ImmVirX — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/immvirx

Wikipedia (cite web)

{{cite web |title=ImmVirX — Funding & Investors |url=https://www.vcbacked.co/company/immvirx |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 5, 2023.